Evolution of ramucirumab in the treatment of cancer - A review of literature - Wikidata - wikimedia - TriplyDB

Evolution of ramucirumab in the treatment of cancer - A review of literature

Evolution of ramucirumab in the treatment of cancer - A review of literature

http://www.wikidata.org/entity/Q28276412

about

Gastric cancer management: Kinases as a target therapy.Site-Specific N-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2.Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Eruptive cherry angiomas developing in a patient treated with ramucirumab.

P2860

Q38749038-68D2CBD2-1CA1-417F-82EE-0B9361FAFBAF Q39102302-6C679F1B-9507-4060-8D6A-65399082A770 Q46219895-BB9E9BEE-3F98-4C16-965F-77A1F9B072A7 Q47221234-7CFE0126-812E-449A-96D0-1F4785FB9FA1 Q49499827-F44BDC04-08AC-4599-BBC3-7B618458DD8F

P2860

Evolution of ramucirumab in the treatment of cancer - A review of literature

http://www.wikidata.org/entity/Q28276412

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Evolution of ramucirumab in the treatment of cancer - A review of literature

@ast

Evolution of ramucirumab in the treatment of cancer - A review of literature

@en

Evolution of ramucirumab in the treatment of cancer - A review of literature

@nl

type

label

Evolution of ramucirumab in the treatment of cancer - A review of literature

@ast

Evolution of ramucirumab in the treatment of cancer - A review of literature

@en

Evolution of ramucirumab in the treatment of cancer - A review of literature

@nl

prefLabel

Evolution of ramucirumab in the treatment of cancer - A review of literature

@ast

Evolution of ramucirumab in the treatment of cancer - A review of literature

@en

Evolution of ramucirumab in the treatment of cancer - A review of literature

@nl

P1433

Q28276412-866E25D7-58BC-4531-AEA4-152D6CDD2DFB

P1476

Q28276412-BF256D39-0DE9-4038-814F-26D01EE72014

P2093

Q28276412-14D896FA-17E1-433F-AFF2-5A2176D62A20

Q28276412-1DEF7F21-4735-4C86-A679-67BAD7FFBEC7

Q28276412-28265C7E-0672-4C81-941D-860073B0282B

Q28276412-4189E046-2573-43D8-B4F4-9F2A65ECC382

Q28276412-4E713A98-439D-4A65-8FF8-EEA1D3708B48

P2860

Q28276412-095FC204-F2C7-4644-9611-7317C01DDBEF

Q28276412-1465B4E1-A5B6-4463-A5CB-A5DF513CC443

Q28276412-198AE5D3-7BA4-4B8D-B693-2EFC523D70E4

Q28276412-24CE2CE0-2199-4803-A765-3500E664B8E2

Q28276412-43FD2867-C8D3-413B-B033-D661BCB75389

Q28276412-444B0B03-206D-4B00-BB25-2D47C09DC4CE

Q28276412-4F3D2D82-3302-44D0-82B7-C473F8EF8A61

Q28276412-50BE005E-919A-4947-B2DB-89035C690CDF

Q28276412-5DE7AA5B-A00C-42D5-A371-58D418BE5B7A

Q28276412-5E04E9BB-B09B-463C-938C-9DDFED760B19

P31

Q28276412-92279AC9-0301-4820-AD25-CA11F55E1770

P356

Q28276412-C4DF7DF9-AEB4-4C86-8C02-F716A6D05377

P407

Q28276412-44D226E8-B959-43F8-8347-BB2DF412A86D

P577

Q28276412-13097EC0-57A0-406D-BB6F-4ED56761C327

P698

Q28276412-76730046-0A14-4EB0-92EF-4E0E10D8FCB1

P356

1078155216655474

P1433

Journal of Oncology Pharmacy Practice

P1476

Evolution of ramucirumab in the treatment of cancer - A review of literature

@en

P2093

A Vennepureddy

http://www.w3.org/2001/XMLSchema#string

J P Atallah

http://www.w3.org/2001/XMLSchema#string

P Singh

http://www.w3.org/2001/XMLSchema#string

R Rastogi

http://www.w3.org/2001/XMLSchema#string

T Terjanian

http://www.w3.org/2001/XMLSchema#string

P2860

What is the evidence that tumors are angiogenesis dependent?

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

P31

scholarly article

P356

10.1177/1078155216655474

http://www.w3.org/2001/XMLSchema#string

P407

P577

2016-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27306885

http://www.w3.org/2001/XMLSchema#string